Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.45), $0.02 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $622.1 million versus the consensus estimate of $601.14 million.

GUIDANCE:

Exact Sciences sees FY2023 revenue of $2.441-2.466 million, versus the consensus of $2.418 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.